Piao W, Li L, Saxena V, Iyyathurai J, Lakhan R, Zhang Y, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nat Commun. 2022;13:2176 pubmed publisher

Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, et al. Targeted immunotherapy for HER2-low breast cancer with 17p loss. Sci Transl Med. 2021;13: pubmed publisher

Georg P, Astaburuaga García R, Bonaguro L, Brumhard S, Michalick L, Lippert L, et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. 2022;185:493-512.e25 pubmed publisher

Cossarizza A, Chang H, Radbruch A, Abrignani S, Addo R, Akdis M, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol. 2021;51:2708-3145 pubmed publisher

Gozgit J, Vasbinder M, Abo R, Kunii K, Kuplast Barr K, Gui B, et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell. 2021;39:1214-1226.e10 pubmed publisher

Zhang X, SABIO E, Krishna C, Ma X, Wang J, Jiang H, et al. Qa-1b Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. Mol Cancer Res. 2021;19:1076-1084 pubmed publisher

Segal N, Cercek A, Ku G, Wu A, Rimner A, Khalil D, et al. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. Clin Cancer Res. 2021;27:2200-2208 pubmed publisher

Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693-698 pubmed publisher